Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac

View through CrossRef
8086 Background: Results of PointBreak were previously reported. Correlative tissue TR results are presented. Methods: Of 939 pts in the intent-to-treat population (ITT), 211 (22.5%) signed TR consent forms and had evaluable samples. Specimens were analyzed for: Epidermal Growth Factor Receptor (EGFR) mutations by polymerase chain reaction (n=132); thyroid transcription factor-1 (TTF-1) (n=205), thymidylate synthase (TS) (n=189), and folate receptor-alpha (FR-α) (n=180) by immunohistochemistry (IHC) (H-scores range, 0-300). H scores were dichotomized based on positive (>0)/negative (=0) cutpoint. Adjusted Cox/logistic regression determined correlations between overall survival (OS), progression-free survival (PFS), response rate (RR), and dichotomous IHC markers. A 2-sided test with α = 0.05 and 0.1 evaluated treatment and interaction effects, respectively. Results: Median (m) OS and mPFS were similar in the ITT and TR populations for both arms. 11/132 (8.3%) pts had activating EGFR mutations. For TS or FR-α, no significant between-arm differences in OS, PFS and RR were seen. 139/205 (67.8%) pts had positive TTF-1 (TTF-1+). TTF-1+ pts, compared with TTF-1-, independent of treatment, had significantly longer mOS (14.9 vs 8.7 mos, HR 0.48, p<0.001), mPFS (6.9 vs 4.5 mos, HR 0.62, p=0.006), and higher RR (38.9% vs 19.7%, OR 2.68, p=0.008). For TTF-1+ pts, compared with Pac arm, Pem arm had longer mOS (17.6 vs 12.8 mos, HR=0.7, p=0.08; interaction p=0.12) and mPFS (7.3 vs 5.8 mos, HR=0.78, p=0.20; interaction p=0.261); although not statistically significant. Conclusions: The number of pts with EGFR mutations was too small to draw conclusions. No significant between-arm differences for TS and FR-α were seen. Longer survival in TTF-1+ pts suggests TTF-1 expression is prognostic. Additional studies will be needed to better understand trends favoring pem for survival among TTF-1+ pts and other prognostic and/or predictive relationships of these markers. Clinical trial information: NCT00762034.
Title: Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac
Description:
8086 Background: Results of PointBreak were previously reported.
Correlative tissue TR results are presented.
Methods: Of 939 pts in the intent-to-treat population (ITT), 211 (22.
5%) signed TR consent forms and had evaluable samples.
Specimens were analyzed for: Epidermal Growth Factor Receptor (EGFR) mutations by polymerase chain reaction (n=132); thyroid transcription factor-1 (TTF-1) (n=205), thymidylate synthase (TS) (n=189), and folate receptor-alpha (FR-α) (n=180) by immunohistochemistry (IHC) (H-scores range, 0-300).
H scores were dichotomized based on positive (>0)/negative (=0) cutpoint.
Adjusted Cox/logistic regression determined correlations between overall survival (OS), progression-free survival (PFS), response rate (RR), and dichotomous IHC markers.
A 2-sided test with α = 0.
05 and 0.
1 evaluated treatment and interaction effects, respectively.
Results: Median (m) OS and mPFS were similar in the ITT and TR populations for both arms.
11/132 (8.
3%) pts had activating EGFR mutations.
For TS or FR-α, no significant between-arm differences in OS, PFS and RR were seen.
139/205 (67.
8%) pts had positive TTF-1 (TTF-1+).
TTF-1+ pts, compared with TTF-1-, independent of treatment, had significantly longer mOS (14.
9 vs 8.
7 mos, HR 0.
48, p<0.
001), mPFS (6.
9 vs 4.
5 mos, HR 0.
62, p=0.
006), and higher RR (38.
9% vs 19.
7%, OR 2.
68, p=0.
008).
For TTF-1+ pts, compared with Pac arm, Pem arm had longer mOS (17.
6 vs 12.
8 mos, HR=0.
7, p=0.
08; interaction p=0.
12) and mPFS (7.
3 vs 5.
8 mos, HR=0.
78, p=0.
20; interaction p=0.
261); although not statistically significant.
Conclusions: The number of pts with EGFR mutations was too small to draw conclusions.
No significant between-arm differences for TS and FR-α were seen.
Longer survival in TTF-1+ pts suggests TTF-1 expression is prognostic.
Additional studies will be needed to better understand trends favoring pem for survival among TTF-1+ pts and other prognostic and/or predictive relationships of these markers.
Clinical trial information: NCT00762034.

Related Results

Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract Introduction Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors
Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors
PURPOSE: To evaluate the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic (PK) profile of paclitaxel and carboplatin when administered every 3 wee...
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessation
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessation
Abstract Background A standard first-line regimen for patients with metastatic non-squamous non-small cell lung cancer (nsqNSCLC) without driver gene mutations is immune ch...

Back to Top